Daiwa Securities Group’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Daiwa Securities Group’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-75	Closed	–	–	1423
2022 Q3	$0	Hold	75	–	–	﹤0.01%	1430
2022 Q2	$0	Hold	75	–	–	﹤0.01%	1463
2022 Q1	$1K	Hold	75	–	–	﹤0.01%	1364
2021 Q4	$1K	Hold	75	–	–	﹤0.01%	1376
2021 Q3	$1K	Hold	75	–	–	﹤0.01%	1299
2021 Q2	$1K	Hold	75	–	–	﹤0.01%	1244
2021 Q1	$1K	Hold	75	–	–	﹤0.01%	1255
2020 Q4	$1K	Buy	+75	New	+$584	﹤0.01%	1236
2018 Q4	–	Sell	-178	Closed	-$1K	–	1200
2018 Q3	$1K	Hold	178	–	–	﹤0.01%	1152
2018 Q2	$1K	Hold	178	–	–	﹤0.01%	1173
2018 Q1	$4K	Buy	+178	New	+$3.95K	﹤0.01%	1095

Other funds holding JNCE

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Daiwa Securities Group's JNCE Position: Q4 2022 in Review

Daiwa Securities Group sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q4 2022, closing a stake of 75 shares.

Daiwa Securities Group first reported a position in JNCE in Q1 2018 and held it in 11 quarters. The position peaked at $4K in Q1 2018. 85 funds tracked by Wall St. Rank hold JNCE as of Q4 2022.

Daiwa Securities Group reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Daiwa Securities Group sold 75 Jounce Therapeutics, Inc. Common Stock shares in Q4 2022.
Daiwa Securities Group first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2018 and held it in 11 quarters.
Daiwa Securities Group's Jounce Therapeutics, Inc. Common Stock position peaked at $4K in Q1 2018.
85 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Daiwa Securities Group's 13F filing for Q4 2022, filed 6 Feb 2023.